Upstream Bio, Inc. SEC filings UPB

Upstream Bio, Inc. has 134 filings in SEC EDGAR's recent list, going back to Jun 12, 2024. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 1, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Form Description Filed Period
SEC STAFF LETTER Filing Oct 16, 2024 —
EFFECT Filing Oct 10, 2024 —
CERT Filing Oct 10, 2024 —
8-A12B Filing Oct 8, 2024 —
CORRESP Letter to the SEC Oct 8, 2024 —
CORRESP Letter to the SEC Oct 8, 2024 —
CORRESP Letter to the SEC Sep 30, 2024 —
CORRESP Letter to the SEC Sep 18, 2024 —
UPLOAD Letter from the SEC Aug 20, 2024 —
DRSLTR Filing Aug 9, 2024 —
DRS/A Filing Aug 9, 2024 —
UPLOAD Letter from the SEC Jul 25, 2024 —
DRSLTR Filing Jul 18, 2024 —
DRS/A Filing Jul 18, 2024 —
SEC STAFF LETTER Filing Jul 9, 2024 —
UPLOAD Letter from the SEC Jul 9, 2024 —
DRS Filing Jun 12, 2024 —

Showing 17 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
UPB (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Waltham, MA
SEC filer status
, Emerging growth company
SEC CIK
2022626

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.